Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease

Koen Poesen1, Maxim De Schaepdryver2, Beatrice Stubendorff2

  • 1From the Laboratory for Molecular Neurobiomarker Research (K.P., M.D.S., B.G.), Laboratory for Cognitive Neurology (R.V.) and Laboratory of Neurobiology (Center for Brain & Disease Research, VIB, Leuven) (P.V.D.), Department of Neurosciences, KU Leuven (University of Leuven); Laboratory Medicine (K.P., M.D.S.) and Department of Neurology (O.S., K.G.C., G.C., A.D., N.L., P.T., D.V.R., R.V., P.V.D.), University Hospitals Leuven, Belgium; Hans Berger Department of Neurology (B.S., T.P., T.M.R., N.F., B.H., M.R., A.R., A.G., O.W.W., J.G.) and Institute for Biochemistry (P.M., S.W., H.R.), Jena University Hospital, Germany; INSERM, U942 (S.G., C.P.), Groupe Hospitalier Lariboisière Fernand-Widal Saint-Louis, CMRR Paris Nord AP-HP, Université Paris Diderot, France. koen.poesen@uzleuven.be.

Neurology
|May 14, 2017
PubMed
Abstract